


CHAPTER

Factors

WINTER 2015



2015:

**A Year in
Review**



**Midwest
Hemophilia
Association**

NOW APPROVED



Visit IXINITY.com for more information.


Call your IXperience Concierge™ at
1-855-IXINITY (1-855-494-6489).

Manufactured by Cangene Corporation, a subsidiary of Emergent BioSolutions Inc. and distributed by Cangene bioPharma, Inc., a subsidiary of Emergent BioSolutions Inc. IXINITY [Coagulation Factor IX (Recombinant)], IXperience Concierge, and any and all Emergent BioSolutions Inc. brand, product, service and feature names, logos, slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All rights reserved.



© 2015 Emergent BioSolutions Inc.
IXI 116-0515

Live your dreams,
we're here for you.



*"We love you guys!
We couldn't ask for more
knowledgeable, friendly, or
caring staff."*

- Family of ARx Patients

ACCURATE Rx
PHARMACY
SPECIALIZING IN NURSING & INFUSION SERVICES

Visit our website: www accuraterx.net

24/7/365 Pharmacist Hotline: 888-335-4279

E-mail: intake@accuraterx.net • Fax: 573-442-6429

Chapter Factors is published by:

The Midwest Hemophilia Association

PO Box 412866
Kansas City, MO 64141
(816) 479-5900
www.midwesthemophilia.org

EXECUTIVE DIRECTOR

MARK COX

(913) 220-9687
mcox@midwesthemophilia.org

BOARD OF DIRECTORS

2015 OFFICERS

AIMEE TEMPERA

PRESIDENT

Cell: (316) 518-0524
aimee@maxsweldingsupplies.com

BROOKE CONNELL

VICE-PRESIDENT

(913) 375-5757
connell_brooke@yahoo.com

DEBBIE NELSON

SECRETARY

Cell: (816) 398-5879
Office: (816) 302-6854
dlnelson@cmh.edu

MARK DUDLEY

TREASURER

Home: (816) 650-4035
Work: (816) 554-6750
mdudley@blueridgebank.net

2015 BOARD MEMBERS

ANGELA BROWN

(314) 952-6265
intangela@yahoo.com

DENNIS HISEK

(816) 820-1543
umden@aol.com

JENNIFER RENTSCHLER

(660) 888-1618
jenr@accuraterx.net

ELLENE SANDER WHITMORE

(816) 377-7174
ellenesw@gmail.com

This material is provided for your general information only. The Midwest Hemophilia Association does not give medical advice or engage in the practice of medicine. The Midwest Hemophilia Association under no circumstances recommends particular treatments for specific individuals. In all cases, it is recommended that individuals consult a physician or local treatment center before pursuing any course of treatment.

Brand names of treatment products are provided for information only. They are not an endorsement of a particular product or company by MHA. Acceptance of advertising for products and services in Chapter Factors in no way constitutes endorsement by the Midwest Hemophilia Association.

© Copyright 2015 by Midwest Hemophilia Association

FROM THE EXECUTIVE DIRECTOR



News and Notes

One of the most important things we do here at MHA is communicate. We communicate event information. We communicate research information. We communicate industry programming. We communicate educational programming. Most importantly we communicate this information to you in a variety of methods including our Chapter Factors newsletter, our MHA Facebook page and through our blast email database and our mailing database. While all are effective the mailing database takes the most time to manage in keeping names and addresses current.



At the last MHA Board Meeting it was agreed upon that we should do an evaluation of our mailing database to learn if there are folks on there that no longer wish to be contacted by mail.

So with that in mind we are asking if you would still like to be on our mailing list. If you do wish to remain on the mailing that is great and you do not need to do anything else. However, if you wish to be removed please contact me by phone or email or clip the form below and mail it to me.

We certainly hope that you will remain on the mailing list. Even if you wish off the mailing list we can add you to the email blast database. We believe it is job one to get you the best information in a timely and responsible manner. Thank you for staying connected!

Mark Cox
Executive Director

Midwest Hemophilia Association Mailing List

If you would like to be **REMOVED** from our mailing list, you may do so by following one of the three options listed below. You can be added back onto the mailing list at any time.

✉ Complete the form below and mail to Midwest Hemophilia Association at
8900 State Line Road, Suite 411, Leawood, Kansas 66206

Name: _____

Address: _____

City/State/Zip: _____

☎ Call Executive Director Mark Cox at **816-479-5900**

@ Or email Executive Director Mark Cox at **mcox@midwesthemophilia.org**



Message from the President

It has been a busy year for Midwest Hemophilia Association! We had the Wichita education event at Laser quest where Angela Brown gave an amazing presentation from the Steps for Living Program. Kansas also hosted its first ever Advocacy Day thanks to Jennifer Rentschler. The Western Kansas education event had a record turnout and was held at the Lee Richardson Zoo in Garden City. John Carlton was the presenter for education. Springfield's education event was again at the Springfield Cardinals game. Brenda Adamson, RN provided the education.

We had an amazing Family Fun Fair this year for our Annual education event. Last but not least how could we forget Camp! This was our first year at our new location, Lake Doniphan. We also had several Industry sponsored education



dinners/events scattered throughout the year in all our regional geographic areas.

In amongst our education we had several fundraisers including the Skeet Shoot, Golf Tournament and Hemophilia Walks.

There were two Skeet Shoots this year, one in Kansas City and the second one just outside of Springfield. The Golf Tournament was again a success and our

three Hemophilia Walks (Kansas City, Springfield and Wichita) raised a lot of awareness and funds to be used for our educational programming. These events take place every year thanks to our amazing chair persons and volunteers. We are in search of a few more committee members to help take over some responsibilities and come up with ideas in their prospective geographic areas.

Here is a list of all the committees and their role for MHA:

- Events/Education
- Wichita Education Event
- Western Kansas Education Event
- Springfield Education Event
- Family Fun Fair
- Skeet Shoot
- Camp
- Golf Tournament
- Hemophilia Walks
- Advocacy (MO and KS)

If any of these committees interest you, please call Mark Cox and he will be able to direct you to the appropriate person.

The future of MHA is still going full steam ahead. We are in the process of developing a new 3 year strategic plan as well as a youth program. We are ramping up our education events with current



Left to Right: Aimee Tempera, MHA President, presents Brooke Connell with the 2015 MHA Volunteer of the Year Award. Congratulations Brooke!



Left: Group picture of the Getting in the Game golf tournament sponsored by CSL Behring held in Phoenix, Arizona. Below Top: Issac Smith with his father, Kevin, at the Whirlwind Golf Course. Below Middle: During the tournament, Issac was assigned his own caddie. Below Bottom: Issac was paired with professional golfer Jordan Zerbini during the tournament.



topics and style of delivery. We are in the process of setting the 2016 calendar of events as of our December 5th Board meeting.

Thanks for a great year everyone!
Can't wait to see y'all in 2016!!!

— Aimee Tempera, President

Getting in the Game

My name is Isaac Smith, I am 10 years old. I was nominated to go to the Getting in the Game golf tournament in Phoenix Arizona, sponsored by CSL Behring. This was the first time I got to fly on a big airplane. It was fun in Phoenix. I got to play golf with a professional golfer who also had hemophilia. The tournament was fun because I had my own caddie. He helped me hit the ball so I could get it in control and it would go far. I liked the Whirlwind Golf Course. The caddie knew a lot about golf, and he helped me get the right angle for putting. At the awards dinner I was sitting at the table with the guy who won first place in the golf tournament. I really enjoyed this trip and hope to go to this event again!



Thank you to our Industry Sponsors

- Accredo
- Accurate Rx
- Affinity Biotech
- ARJ Infusion Services
- AxelaCare
- Baxalta
- Bayer Healthcare
- BioEthics Advantage
- Biogen
- BioRx
- Children's Mercy Hemophilia Care
- CSL Behring
- Emergent
- Grifols USA
- HPC International
- Midwest-IV
- National Cornerstone Healthcare
- Novo Nordisk
- Soleo Health
- Option Care
- Pfizer



SUPERIOR BIOLOGICS

Making a difference in Peoples' lives

EXPERTISE IN:

- Hemophilia A
- Hemophilia B
- Von Willebrand's Disease
- Other Bleeding Disorders

SERVICES INCLUDE:

- Nursing & Pharmacy 24/7
- Infusion Education & Training
- Reimbursement Specialists
- Direct Communication with the People You Know
- Same Day Delivery

Craig MacDonald
Regional Territory Manager
760-485-8281

Brian Rodgers
Hemophilia Specialist
816.726.9091

Office: 866.416.3655
Fax: 866.416.3656

ARJ Infusion SERVICES

Where caring is...



...the ultimate Factor

866.451.8804

www.arjinfusion.com

- Award Winning Nursing
- Licensed Home Health Agency
- Pharmacy Onsite
- 24 Hour On-call Service
- Reimbursement Experts
- Infusion Education for Patients and Families



Specializing In ...

Hemophilia
Bleeding Disorders
Von Willebrand's Disease



WANT TO KNOW MORE ABOUT YOUR FACTOR OPTIONS?

To learn more about these options, contact your CoRe Manager:

Vicki Oberkrom
Phone: 660.281.2447
E-mail: Vicki.Oberkrom@biogenidec.com



When it comes to your factor therapy, you have choices. And at Biogen Idec, we recognize the importance of researching and delivering additional factors to the hemophilia community. See if now might be the right time for you to make a change—learn more about our therapy options as well as our range of financial, educational, and community support programs.

biogen idec. © 2015 Biogen Idec. All rights reserved. HEM-1007117 07/14

2016

Calendar of Events

We have some amazing events planned for 2016!

Please join us for any or all of these events to celebrate and support hemophilia awareness. Watch your mail and check our website throughout the year for more event details.

Clip and save this calendar for reference so you don't miss out!



January

January 30, 2016

Wichita Education Event

*Laser Quest
Wichita, Kansas*

March

Missouri & Kansas

Advocacy Days

Dates to be announced

April

April 23, 2016

KC Pull for a Cure -

A Sporting Clay Event

*Powder Creek Shooting Park
Lenexa, Kansas*

April 30, 2016

Western Kansas Event

Location to be announced

June

June 25, 2016

Springfield Education Event

*White River Conference Center
Springfield, Missouri*

July

July 31, 2016 - August 5, 2016

MHA Summer Camp

*Lake Doniphan Conference
& Retreat Center
Excelsior Springs, Missouri*

August

August 13, 2016

**Ozarks Pull for a Cure -
A Sporting Clay Event**

*Ozark Shooters Sporting Complex
Walnut Shade, Missouri*

September

September 9, 2016

MHA Annual Golf Tournament

*Drumm Farm Golf Club
Independence, Missouri*

September 10 - 11, 2016

MHA Family Fun Fair

*Hilton Garden Inn
Independence Missouri*

October

October 8, 2016

Kansas City Hemophilia Walk

*Shawnee Mission Park
Shawnee, Kansas*

October 16, 2016

Wichita Hemophilia Walk

*Exploration Place
Wichita, Kansas*

November

MHA Award Banquet

Date to be announced

www.midwesthemophilia.org

2015: A YEAR IN REVIEW



GOLF TOURNAMENT



Kansas City Pull for a Cure



Family Fun



SUMMER CAMP



VIEW

h Fair




Hemophilia Walks

KANSAS CITY



SPRINGFIELD



WICHITA



NHF Washington Days



MEN'S RETREAT

Biotherapies for Life[®] CSL Behring

Introducing...

my Access[®]

Tap into My Access to help manage your condition—or your loved one's—in a cost-effective manner

designed to help you cover the out-of-pocket costs associated with your therapy

ACCESSED through the My SourceSM program

Available for reenrollment every year

For more information or to enroll, call the My Source Hotline at **1-800-676-4266** to speak with a My Source Care Coordinator.

Visit www.MySourceCSL.com.



- www.facebook.com/HemophiliaAndU
- www.facebook.com/vonWillebrandAndU
- <https://twitter.com/MySourceCSL>
- <http://instagram.com/MySourceCSL>



Biotherapies for Life[®], My Access[®] and My Source Tap into itSM are registered trademarks and My SourceSM is a service mark of CSL Behring LLC.
©2015 CSL Behring LLC, 1025 First Avenue, PO Box 61501, King of Prussia, PA, 19406-0501 USA
www.CSLBehring.com www.MySourceCSL.com CSL1402001811 10/2015

HELPFUL NUMBERS

KANSAS CITY REGIONAL HEMOPHILIA CENTER
1-816-302-6869 • 1-800-236-1713

Dr. Shannon Carpenter • Dr. William Jennings
Dr. Brian Wicklund • Dr. Jill Moormeier
Katie Foote, LMSW • Andrew Wilson, RN, CFNP
Melissa Armanees, RN, CPNP

**UNIVERSITY OF MISSOURI
HOSPITAL AND CLINICS
HEMOPHILIA TREATMENT CENTER**
1-573-882-9355


Dr. Barbara Gruner • Dr. Carl Freter
Dr. Tamara Hopkin • Lauren Grana, MSW

NATIONAL HEMOPHILIA FOUNDATION (NHF)
1-800-42-HANDI • www.hemophilia.org



BAYER HEALTHCARE AND THE HEMOPHILIA COMMUNITY

commitment, leadership & innovation



For information on Bayer's Educational Patient and Community Resources, contact your Hematology Account Executive by calling **1-888-79-BAYER**.

©2014 Bayer HealthCare Pharmaceuticals Inc. All rights reserved. BAYER and the Bayer Cross are registered trademarks of Bayer. Printed in USA 03/14 KN10000614B



UNLOCKING YOUR SELF-POTENTIAL

ADVATE
[Antihemophilic Factor (Recombinant)]
There's more to life.



ADVATE HAS A PROVEN SAFETY PROFILE¹⁻⁷

Low risk of inhibitor development in previously treated patients (PTPs) demonstrated in clinical studies¹⁻⁵



(95% confidence interval, 0.02%–2.13%)

6 CLINICAL STUDIES / **270** PATIENTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA A

- **1 low-titer, nonpersistent inhibitor (<1%)** in a pivotal study^{*†‡} (n=108)
- **0 inhibitors** in a continuation study^{*†‡} (n=82); a pediatric study^{†‡} (n=53); a surgery study^{*†‡} (n=59); a Japanese study[‡] (n=15); and a prophylaxis study^{*§†} (n=73)

*Patients with an estimated ≥ 150 factor VIII exposure days.^{1,3,4}

†Some patients participated in more than 1 study.²

‡Patients with an estimated ≥ 50 factor VIII exposure days.⁵

§There was 1 case of a possible low-titer factor VIII inhibitor, which was unconfirmed, unaccompanied by symptoms of inhibitor presence, and disappeared at the subject's subsequent test.¹

ADVATE [Antihemophilic Factor (Recombinant)] Important Information Indications

ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called "classic" hemophilia).

ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A.

Your healthcare provider may give you ADVATE when you have surgery.

ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

DETAILED IMPORTANT RISK INFORMATION

You should not use ADVATE if you:

- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.

Tell your healthcare provider if you are pregnant or breastfeeding because ADVATE may not be right for you.

You should tell your healthcare provider if you:

- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

You can have an allergic reaction to ADVATE.

Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

Side effects that have been reported with ADVATE include: cough, headache, joint swelling/aching, sore throat, fever, itching, dizziness, hematoma, abdominal pain, hot flashes, swelling of legs, diarrhea, chills, runny nose/congestion, nausea/vomiting, sweating, and rash.

Tell your healthcare provider about any side effects that bother you or do not go away or if your bleeding does not stop after taking ADVATE.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see following page for Brief Summary of ADVATE full Prescribing Information.

References: 1. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management [published correction appears in *J Thromb Haemost.* 2012;10(6):1204]. *J Thromb Haemost.* 2012;10(3):359-367. 2. Shapiro A, Gruppo R, Pabinger I, et al. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. *Expert Opin Biol Ther.* 2009;9(3):273-283. 3. Tarantino MD, Collins PW, Hay CRM, et al. and the rAHF-PFM Clinical Study Group. Clinical evaluation of an advanced category antihemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. *Haemophilia.* 2004;10(5):428-437. 4. Négrier C, Shapiro A, Berntorp E, et al. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. *Thromb Haemost.* 2008;100(2):217-223. 5. Blanchette VS, Shapiro AD, Liesner RJ, et al. for the rAHF-PFM Clinical Study Group. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. *J Thromb Haemost.* 2008;6(8):1319-1326. 6. Oldenburg J, Goudemand J, Valentino L, et al. Postauthorization safety surveillance of ADVATE [antihemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. *Haemophilia.* 2010;16(6):866-877. 7. Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. *Thromb Haemost.* 2012;107(6):1072-1082.



[Antihemophilic Factor (Recombinant)]

Important facts about

ADVATE [Antihemophilic Factor (Recombinant)]

This leaflet summarizes important information about ADVATE. Please read it carefully before using this medicine. This information does not take the place of talking with your healthcare provider, and it does not include all of the important information about ADVATE. If you have any questions after reading this, ask your healthcare provider.

What is the most important information I need to know about ADVATE?

Do not attempt to do an infusion to yourself unless you have been taught how by your healthcare provider or hemophilia center.

You must carefully follow your healthcare provider's instructions regarding the dose and schedule for infusing ADVATE so that your treatment will work best for you.

What is ADVATE?

ADVATE is a medicine used to replace clotting factor (factor VIII or antihemophilic factor) that is missing in people with hemophilia A (also called "classic" hemophilia). The product does not contain plasma or albumin. Hemophilia A is an inherited bleeding disorder that prevents blood from clotting normally.

ADVATE is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A.

Your healthcare provider may give you ADVATE when you have surgery. ADVATE can reduce the number of bleeding episodes in adults and children (0-16 years) when used regularly (prophylaxis).

ADVATE is not used to treat von Willebrand disease.

Who should not use ADVATE?

You should not use ADVATE if you:

- Are allergic to mice or hamsters.
- Are allergic to any ingredients in ADVATE.

Tell your healthcare provider if you are pregnant or breastfeeding because ADVATE may not be right for you.

How should I use ADVATE?

ADVATE is given directly into the bloodstream.

You may infuse ADVATE at a hemophilia treatment center, at your healthcare provider's office or in your home. You should be trained on how to do infusions by your healthcare provider or hemophilia treatment center. Many people with hemophilia A learn to infuse their ADVATE by themselves or with the help of a family member.

Your healthcare provider will tell you how much ADVATE to use based on your weight, the severity of your hemophilia A, and where you are bleeding.

You may have to have blood tests done after getting ADVATE to be sure that your blood level of factor VIII is high enough to clot your blood.

Call your healthcare provider right away if your bleeding does not stop after taking ADVATE.

What should I tell my healthcare provider before I use ADVATE?

You should tell your healthcare provider if you:

- Have or have had any medical problems.
- Take any medicines, including prescription and non-prescription medicines, such as over-the-counter medicines, supplements or herbal remedies.
- Have any allergies, including allergies to mice or hamsters.
- Are breastfeeding. It is not known if ADVATE passes into your milk and if it can harm your baby.
- Are pregnant or planning to become pregnant. It is not known if ADVATE may harm your unborn baby.
- Have been told that you have inhibitors to factor VIII (because ADVATE may not work for you).

What are the possible side effects of ADVATE?

You can have an allergic reaction to ADVATE.

Call your healthcare provider right away and stop treatment if you get a rash or hives, itching, tightness of the throat, chest pain or tightness, difficulty breathing, lightheadedness, dizziness, nausea or fainting.

Side effects that have been reported with ADVATE include:

cough	headache	joint swelling/aching
sore throat	fever	itching
dizziness	hematoma	abdominal pain
hot flashes	swelling of legs	diarrhea
chills	runny nose/congestion	nausea/vomiting
sweating	rash	

Tell your healthcare provider about any side effects that bother you or do not go away.

These are not all the possible side effects with ADVATE. You can ask your healthcare provider for information that is written for healthcare professionals.

What else should I know about ADVATE and Hemophilia A?

Your body may form inhibitors to factor VIII. An inhibitor is part of the body's normal defense system. If you form inhibitors, it may stop ADVATE from working properly. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to factor VIII.

Medicines are sometimes prescribed for purposes other than those listed here. Do not use ADVATE for a condition for which it is not prescribed. Do not share ADVATE with other people, even if they have the same symptoms that you have.

The risk information provided here is not comprehensive. To learn more, talk with your health care provider or pharmacist about ADVATE. The FDA approved product labeling can be found at www.ADVATE.com or 1-888-4-ADVATE.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Baxter Healthcare Corporation
Westlake Village, CA 91362 USA

U.S. License No. 140

Issued: 05/2015

USBS/34/15-0077

Baxter

It's Time to Help Support Your Hemophilia Treatment Center

Just make the choice to get your factor from the Children's Mercy Hospital 340B program and you are helping to support your HTC team... it's that simple! All proceeds go to support the specialized clinicians, physical therapy, training, and other essential services you and your family have come to depend on at Children's Mercy Hospital.

Did you know that our factor program provides:



- Peace of mind... Hematologists are on call 24 hours a day, 7 days a week
- All brands of factor in a wide assortment of vial sizes
- A broad list of infusion supplies
- Customer Care Coordinators who know Hemophilia and are ready to be of assistance
- Interpreters who are fluent in over 180 different languages
- Coordination of in-home nursing services
- Shipments to your home or choice of location

Contact us at 816-221-4544
Ask for Cyndi Donate



Children's Mercy

GRIFOLS

Alphanate®

Antihemophilic Factor/von Willebrand Factor Complex (Human)

AlphaNine® SD

Coagulation Factor IX (Human)
Solvent Detergent Treated/Virus Filtered

INTRODUCING
The Pay As Little As \$0 Copay Program

Dear Valued Customer:

On January 1 2015, Grifols will launch a new and improved copay card program for patients on ALPHANATE and AlphaNine SD.

Program Information:

- Patients may be eligible for up to \$20,000 in coverage annually for the cost of their ALPHANATE or AlphaNine SD prescriptions
- No monthly maximums
- No waiting period; patients may use the offer as soon as they enroll
- No income requirement
- Program enrollment is required
- Restrictions apply
 - Patients must have commercial insurance
 - Patients must have a valid ALPHANATE or AlphaNine SD prescription
 - Patients may not participate in Medicare Part D, Medicaid, Medigap, Veteran's Affairs, Department of Defense, TRICARE, or any other federal or state-funded programs or be enrolled in a health plan that does not permit members to participate in copay assistance programs

How to enroll:

ALPHANATE Pay as Little as \$0 CoPay program

- Visit www.alphanatecard.com or call (877) 255-4829 and speak with a customer experience center support person

AlphaNine SD Pay as Little as \$0 CoPay program

- Visit www.alphaninecard.com or call (877) 264-1405 and speak with a customer experience center support person



Researchers Learn More about FVIII Origins

In breakthrough research, Rice University (RU) scientists have uncovered more about the cellular origins of factor VIII (FVIII), a protein that plays a critical role in the blood clotting process. The study paper was co-authored by research biochemist Nancy A. Turner, BA, and hematologist Joel L. Moake, MD, at RU's Department of Bioengineering.

Earlier studies established that FVIII is produced in endothelial cells that line the walls of blood vessels in organs such as the heart, liver and intestines. RU investigators have delved further by looking for the specific source of FVIII generation and deployment from within different types of endothelial cells.

Turner and Moake's experiments focused on human umbilical vein endothelial cells (HUVECs), which are found in large veins, and glomerular microvascular endothelial cells (GMVECs), which are located in the smallest capillaries of the kidneys. Although the presence of FVIII in these types of cells had not been previously confirmed, investigators had recognized them, particularly HUVECs, as a viable focus of research for several reasons.

"HUVECs are the generic human endothelial cells that (biological researchers) use the first time they do anything," Turner said. "They're cheap. They're easy to work with, and they've been the model for endothelial cells for, I don't know, at least 50 years."

With her expertise in biochemistry, Turner first conducted a series of lab tests to verify the presence of FVIII in HUVECs and GMVECs. Follow-up research confirmed that FVIII is not only synthesized in HUVECs and GMVECs, but is also stored in and secreted from Weibel-Palade bodies (WPBs) within these cells. WPBs are specialized organelles (part of a cell with a specific function) that also contain von Willebrand factor (VWF), another critical protein that binds to FVIII during the clotting cascade. VWF works as a carrier for FVIII as it circulates in the bloodstream.

This discovery has future potential therapeutic significance for people with bleeding disorders. "Now that we recognize that factor VIII is normally synthesized in endothelial cells and stored in Weibel-Palade bodies, those become the precise, most effective physiological targets for gene delivery," concluded Moake.

The article, "Factor VIII Is Synthesized in Human Endothelial Cells, Packaged in Weibel-Palade Bodies and Secreted Bound to ULVWF Strings," was published online October 16, 2015, in the journal PLOS ONE. ■

— Source: Rice University news release dated November 2, 2015

Relax...

We take the worry out of living with hemophilia and other bleeding disorders, so you can enjoy life.



We're looking out for you.

- An individual case member will assist you, advise you and negotiate for you.
- Prescription fulfillment
- Product delivery
- Full line of factor products and custom foil-wrap packaging that maintains proper temperature
- Insurance reimbursement & care provider issues

We're ready to start serving you today.
www.nchswecare.com



Craig Looney • Mimi Law • Anna Mac Donald
(888) 522-3681 "Se Habla Espanol"

Skilled Pharmacists. Experienced Infusion Nurses. Dedicated Patient Experience Team.

Soleo Health provides a team approach to bleeding disorder therapy management.

To learn more, contact
John Kowalski or **Ed Chomyak**
at **913.661.0100**.



SOLEO HEALTH

Innovators in Specialty Infusion

www.soleohealth.com   

MOVING? New Address

Name

Address

City

State

ZIP

(Area Code) Phone Number

E-Mail Address

MAIL TO: MHA • PO Box 412866 • Kansas City, MO 64141

E-MAIL TO: info@midwesthemophilia.org



**Midwest
Hemophilia
Association**

PO Box 412866

Kansas City, MO 64141

Give the Gift of a Lifetime

You can support the Midwest Hemophilia Association by making a planned giving gift. Whether it is a gift of your estate, a trust gift, stock or life insurance you can give to MHA with a gift that won't alter your daily financial commitments.

A planned gift is a tried and true method of charitable giving. It's the gift that keeps on giving and enables you to support MHA and those with bleeding disorders in perpetuity.

So when you are talking about your estate gifts, please consider a planned gift to the Midwest Hemophilia Association.



**Midwest
Hemophilia
Association**

